Announcements & Disclosures
Quarterly Announcements & Disclosures
Notice for the Extra-Ordinary General MeetingProceedings of the Extra-Ordinary General MeetingVoting Results of Extra-Ordinary General Meeting dated 26th April 2021Detail of Independent Directors Familiarisation Program 2020-21Notice for the Extra-Ordinary General Meeting scheduled on 8th June 2021Notice of Board Meeting on 12th May 2021Notice of Board Meeting on 17th May 2021Outcome of Board Meeting held on 12th May 2021Corrigendum to outcome of Board Meeting held on 12th May 2021Outcome of Board Meeting held on 17th May 2021Outcome of Board Meeting held on 25th May 2021Clarification to Outcome of Board Meeting held on 25th May 2021SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of PDP-716 for the Treatment of Open Angle Glaucoma or Ocular HypertensionIndependent Auditor’s Report on compliance with conditions of the Proposed Preferential IssueVoting Results of Extra-Ordinary General Meeting dated 8th June 2021Related Party Disclosure for half year ended on 31st March 2021
Outcome of the meeting of the Securities Allotment Committee held on July 08, 2021Notice of Board Meeting on 26th July 2021Outcome of the Board Meeting held on July 26, 2021 Outcome of the meeting of the Securities Allotment Committee held on August 25, 2021Notice of Board Meeting on 01st September 2021Outcome of the Board Meeting held on 01st September 2021Notice for the 16th Annual General MeetingBusiness Responsibility ReportAnnual Return Newspaper PublicationNewspaper Publication
Quarterly Announcements & Disclosures
Quarterly Announcements & Disclosures
Notice of Board Meeting on 29th July 2019Proceedings of 14th Annual General MeetingVoting Results of 14th Annual General MeetingNotice of Board Meeting on 4th November 2019Related Party Disclosures for half year ended on 30th September 2019Update on Taclantis® Investor Presentation – Update on R&D PipelinePress Release – Audio Playback for Update on R&D Pipeline
Quarterly Announcements & Disclosures
Allotment of 6060606 equity shares on conversion of warrantsAchievement of milestone - commercialisation of XELPROS ™ Shareholding Pattern - 11th January 2019 POSTNotice of Board Meeting on 4th February 2019Receipt of Demand Order from the Office of Commissioner of GST & Central ExciseReturn of Product Rights by partner for ELEPSIA ™ XR 1000/1500mgMandatory Dematerialization for Transfer of Securities
Quarterly Announcements & Disclosures
Details of Independent Directors familiarisation Program - 2016-17Notice of Board Meeting on 5th May 2017Outcome of Board Meeting held on 5th May 2017Notice of EGM - 2nd June 2017Notice for the 12th Annual General MeetingUpdate on Elepsia XRTM (Levetiracetam extended-release tablets 1000 mg and 1500 mg) NDA
Quarterly Announcements & Disclosures
Notice - Completion of dispatch & remote e-voting at 11th AGMNotice of Board Meeting on 29th July 2016Press Release - Update on NCE and NDDS ProgramsProceedings of the 11th Annual General Meeting held on 29th July 2016 Voting Results of 11th Annual General MeetingPostal Ballot Notice and Form - August 2016News Paper Notice - Postal Ballot 2016Results of Postal Ballot 2016
